WO2010133015A1 - Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci - Google Patents

Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci Download PDF

Info

Publication number
WO2010133015A1
WO2010133015A1 PCT/CN2009/001409 CN2009001409W WO2010133015A1 WO 2010133015 A1 WO2010133015 A1 WO 2010133015A1 CN 2009001409 W CN2009001409 W CN 2009001409W WO 2010133015 A1 WO2010133015 A1 WO 2010133015A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
weight
paeoniflorin
parts
licorice
Prior art date
Application number
PCT/CN2009/001409
Other languages
English (en)
Chinese (zh)
Inventor
张作光
Original Assignee
陈婷
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈婷 filed Critical 陈婷
Priority to CN200980159383.4A priority Critical patent/CN102438630B/zh
Publication of WO2010133015A1 publication Critical patent/WO2010133015A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • composition for treating depression preparation method and use thereof
  • the invention belongs to the field of medical technology.
  • the present invention relates to a pharmaceutical composition for treating depression and a process for the preparation thereof.
  • the invention further relates to a method of the pharmaceutical composition for the preparation of a medicament, a health food and/or a barrier or condition. Background technique
  • Depression is the main type of mood disorder and is a syndrome characterized by significant and persistent low mood. Depression is a common and frequently-occurring disease that is harmful to human health. It is a major global mental problem. According to statistics, about 25% of women in the general population have experienced depression in their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology). Information provided by the World Health Organization: The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that depression will rise in the next 20 years. It is the second most common disease in the world.
  • antidepressant drugs in the domestic and international markets are mainly serotonin reuptake inhibitors (SSRIs) such as Baiyoujie, Selot, Zoloft, etc., and their mechanism of action is through regulation of human monoamine neurotransmitters5.
  • Ingredients such as serotonin alleviate depressive symptoms.
  • These drugs have varying degrees of side effects. Studies have shown that "the complex ampoules contained in these drugs have a role in balancing the body's functions, but more often, they still can't calm the patients.”, In recent years, Baiyoujie, etc. Whether the drug of depression is harmful has become a serious social problem.
  • Selot has been found to have potential safety hazards as early as 1996. It has been recalled from the market since 2001.
  • pharmaceutically acceptable carriers and excipients refers to those materials which are well known in the art for use as fillers or carrier materials in pills, tablets, capsules and the like. Substances are generally approved by health care professionals for this purpose and as inactive ingredients of pharmaceutical agents. Compilation of pharmaceutically acceptable carriers and excipients can be found in the Handbook of Pharmaceutical excipients, 2nd edition, by A. Wade and P. J. Weller, ed.; American Pharmaceutical Association, Washington and The
  • terapéuticaally effective amount refers to an amount of a drug that is required to produce an effective effect, which can be varied, and ultimately by the medical practitioner, depending on the route of administration, the type of formulation, the age and weight of the recipient. , and the nature and severity of the disease being treated are determined by many factors. It is an object of the present invention to provide a pharmaceutical composition for treating depression.
  • Another object of the present invention is to provide a method of preparing the above pharmaceutical composition.
  • the present invention provides the following technical solutions:
  • the invention provides a pharmaceutical composition for treating depression, the pharmaceutical composition comprising the following active ingredients:
  • the glycyrrhizic acid or glycyrrhetic acid is 0.1-2 parts by weight, the paeoniflorin is 0.4-8 parts by weight and the paeoniflorin is 0.15-5 parts by weight;
  • the glycyrrhizic acid or glycyrrhetinic acid is 0.2-0.6 parts by weight, the paeoniflorin is 1.2-3.5 parts by weight and the paeoniflorin is 0.4-2 parts by weight;
  • the glycyrrhizic acid or glycyrrhetinic acid is 0.3 parts by weight, the paeoniflorin is 0.6 parts by weight and the paeoniflorin is 0.4 parts by weight.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient; preferably, the pharmaceutical composition is selected from the group consisting of: an oral preparation, a parenteral preparation, a topical and inhaled preparation. And transdermal formulations;
  • the dosage form is an oral preparation selected from the group consisting of: tablets, capsules, powders, granules, pills, drops, juices and syrups;
  • the pharmaceutically acceptable carrier or excipient is selected from the group consisting of: a disintegrant, a lubricant, a binder, a filler, a solvent, a fragrance, a sweetener, an antioxidant.
  • the invention provides a method of preparing the above pharmaceutical composition, the method comprising the steps of:
  • the licorice is 5 to 100 parts by weight, and the chalk is 10 to 600 parts by weight; preferably, the licorice is 10 to 60 parts by weight, and the chalk is 40 to 200 parts by weight; most preferably The licorice is 20 parts by weight, and the chalk is 60 parts by weight.
  • the present invention provides the use of a pharmaceutical composition prepared from licorice and peony as a raw material for the preparation of a medicament for the treatment of depression, a health food and/or a nutrient.
  • the present invention provides the use of a pharmaceutical composition prepared from licorice and peony as a raw material for the preparation of a medicament, health food and/or nutrient for simultaneously treating depression and a disease, disorder or condition therewith. ;
  • the disease, disorder or condition is selected from the group consisting of anxiety, sleep disorders and post-traumatic stress disorder.
  • the present invention provides a pharmaceutical composition prepared by using a licorice extract and a white peony extract as an active ingredient, for the preparation of a medicament for treating depression, a health food and/or a nutrient; preferably, The pharmaceutical compositions are free of other active ingredients.
  • the present invention provides a pharmaceutical composition prepared by using a licorice extract and a white peony extract as active ingredients in the preparation of a medicament, a health food, and/or a medicament for simultaneously treating depression and a disease, disorder or condition complicated therewith. Use in nutraceuticals;
  • the disease, disorder or condition is selected from the group consisting of anxiety, sleep disorders and post-traumatic stress disorder; and/or
  • the pharmaceutical composition is free of other active ingredients.
  • the present invention provides the use of the pharmaceutical composition for the preparation of a medicament, health food and/or nutrient for the treatment of depression.
  • the present invention provides the use of the pharmaceutical composition for the preparation of a medicament, a health food and/or a nutrient for simultaneously treating depression and a disease, disorder or condition therewith; preferably, the disease, The disorder or condition is selected from the group consisting of anxiety, sleep disorders, and post-traumatic stress disorder.
  • the invention provides a method of treating depression, the method comprising administering to a subject a therapeutically effective amount of a licorice extract and a white peony extract.
  • the present invention provides a method of simultaneously treating depression and a disease, disorder or condition therewith, the method comprising administering to the subject a therapeutically effective amount of a licorice extract and a white peony extract;
  • the disease, disorder or condition is selected from the group consisting of anxiety, sleep disorders and post-traumatic stress disorder.
  • the invention provides a method of treating depression, the method comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition;
  • the therapeutically effective daily dose of the pharmaceutical composition is preferably: glycyrrhizic acid or glycyrrhetinic acid
  • the present invention provides a method of simultaneously treating depression and a disease, disorder or condition therewith, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition;
  • the therapeutically effective daily dose is preferably: glycyrrhizic acid or glycyrrhetinic acid
  • the disease, disorder or condition is selected from the group consisting of anxiety, sleep disorders and post-traumatic stress disorder.
  • the present invention will be further described below:
  • the pharmaceutical composition of the present invention comprises a licorice and a white peony group, and comprises at least one selected from the following parts by weight:
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient;
  • the pharmaceutical composition is selected from the group consisting of: an oral preparation, a parenteral preparation, a topical and inhaled preparation, and a transdermal preparation;
  • the dosage form is an oral preparation selected from the group consisting of tablets, capsules, powders, granules, pills, drops, juices and syrups;
  • the pharmaceutically acceptable carrier or excipient is selected from the group consisting of: a disintegrant, a lubricant, a binder, a filler, a solvent, a fragrance, a sweetener, an antioxidant.
  • the obtained extract is obtained by mixing and pulverizing the obtained pharmaceutical composition, and preferably, the licorice extract obtained by water extraction and alcohol precipitation and the white peony extract obtained by purifying the column by water permeation.
  • the licorice extract contains 0.1-2 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, and the white peony extract contains 0.4 to 8 parts by weight of paeoniflorin and 0.15 to 5 parts by weight of paeoniflorin;
  • the licorice extract comprising 0.2 to 0.6 parts by weight of a glycyrrhizic acid or the glycyrrhetinic acid, the albiflorin peony extract containing 1.2-3.5 parts by weight of paeoniflorin and 0.4 to 2 parts by weight ; Further preferably, the licorice extract contains 0.3 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, and the white peony extract contains 0.6 parts by weight of paeoniflorin and 0.4 part by weight of paeoniflorin.
  • the pharmaceutical composition of the present invention may also be directly pulverized by using glycyrrhizic acid or glycyrrhetinic acid together with paeoniflorin and paeoniflorin, and the pharmaceutical composition contains 0.1-2 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, 0.4-8 by weight. a portion of paeoniflorin and 0.15 to 5 parts by weight of paeoniflorin;
  • the weight ratio of the glycyrrhizic acid or glycyrrhetinic acid to the paeoniflorin and the weight ratio of the paeoniflorin are 0.2 to 0.6: 1.2-3.5: 0.4-2;
  • the weight ratio of the glycyrrhizic acid or glycyrrhetinic acid to the paeoniflorin and the weight ratio of the paeoniflorin are 0.3:0.6:0.4.
  • Another object of the present invention is to provide a method of preparing the above pharmaceutical composition.
  • Method 1 the method includes:
  • the pharmaceutical composition is prepared by mixing licorice and white peony (preferably ultrafine pulverization); the licorice is 5 to 100 parts by weight, and the chalk is 10 to 600 parts by weight;
  • the licorice is 10 to 60 parts by weight, and the chalk is 40 to 200 parts by weight; most preferably, the licorice is 20 parts by weight, and the chalk is 60 parts by weight.
  • Method two the method includes:
  • the licorice is 5 to 100 parts by weight, and the chalk is 10 to 600 parts by weight; preferably, the licorice is 10 to 60 parts by weight, and the chalk is 40 to 200 parts by weight; most preferably The licorice is 20 parts by weight, and the chalk is 60 parts by weight.
  • Method three the method comprises:
  • the pharmaceutical composition is prepared by directly mixing and crushing glycyrrhizic acid (or glycyrrhetinic acid) with paeoniflorin and paeoniflorin;
  • the pharmaceutical composition has 0.1 to 2 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid), and contains 0.4-8 parts by weight of paeoniflorin and 0.15 to 5 parts by weight of paeoniflorin;
  • it contains 0.2-0.6 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid), 1.2-3.5 parts by weight of paeoniflorin and 0.4 to 2 parts by weight of paeoniflorin; Further preferably, it contains 0.3 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid), 0.6 parts by weight of paeoniflorin, and 0.4 part by weight of paeoniflorin.
  • the above pharmaceutical composition is a core component for achieving the object of the present invention.
  • those skilled in the art can routinely apply the above pharmaceutical composition and extract composition according to the theory of traditional Chinese medicine or related modern pharmacological theory. Addition and subtraction. Such conventional addition and subtraction is a general technical activity of those skilled in the art, as long as it is a general technical addition or subtraction based on the formulation of the pharmaceutical composition and the extract composition of the present invention, both of which are in the present invention. Within the scope of protection.
  • compositions described above include a pharmaceutically acceptable carrier or excipient which can be processed into any pharmaceutically acceptable oral dosage form (tablets, capsules or powders, etc.).
  • the pharmaceutical composition of the present invention can be formulated into a botanical preparation, a health food and/or a nutrient for the treatment of depression.
  • the pharmaceutical composition of the present invention is useful for treating depression and diseases, disorders or conditions associated therewith.
  • the disease, disorder or condition is selected from the group consisting of anxiety, sleep disorders and post-traumatic stress disorder.
  • the present invention has the following distinct advantages:
  • the main active ingredients of anti-depressant of Radix Paeoniae Alba are paeoniflorin and paeoniflorin, in which paeoniflorin inhibits ATPase and increases AC activity to enhance cAMP content in cytoplasm;
  • the main active constituents of licorice anti-depression are glycyrrhizic acid and licorice Coumarin and the like are cAMP phosphodiesterase inhibitors.
  • the white peony and licorice group can activate the cAMP-PKA pathway in the brain region by multiple targets, and promote the phosphorylation of CREB, which enhances the anti-suppressive effect.
  • the traditional Chinese medicine prescription Zhigan Tang is also only used in the prescription of white peony and licorice, but its indications do not include depression, and the prescription ratio of ⁇ and its preparation method are also related to the medicine of the present invention.
  • the pharmaceutical composition of the present invention has obvious advantages over the glutinous soup in terms of composition, preparation and indications.
  • FIG. 1 is a process flow diagram of a method for preparing a pharmaceutical composition of the present invention using licorice and chalk as raw materials;
  • Fig. 3 is a process flow diagram showing a method of directly mixing licorice and white peony to prepare a pharmaceutical composition of the present invention. The best way to implement the invention
  • This embodiment provides a preferred method for preparing a pharmaceutical composition of the present invention using licorice and chalk as a raw material, the operation comprising the following steps:
  • This embodiment provides a preferred method for preparing a pharmaceutical composition of the present invention directly from a licorice extract and a white peony extract, the operation comprising the steps of:
  • This example provides a preferred method of preparing a pharmaceutical composition of the present invention directly by mixing licorice and white peony, the operation comprising the steps of:
  • the pharmaceutical composition of the present invention was obtained by directly mixing 1.5 kg of licorice with 14 kg of white peony and then super-pulverizing.
  • Experimental Example 4 Effects of extracts of Angelica sinensis (B) and Glycyrrhiza uralensis (G) on the time of mouse tail suspension
  • This embodiment is a preferred combination of the pharmaceutical composition of the present invention having an antidepressant effect, according to the effect of the white peony extract (B) and the licorice extract (G) of the pharmaceutical composition of the present invention on the time of suspension of the mouse. .
  • Test drugs B (white peony extract in Example 1), G ( licorice extract in Example 1); positive drug: fluoxetine hydrochloride ⁇ (baiyou solution), purchased from Lilly Suzhou Pharmaceutical Co., Ltd. Co., Ltd., batch number: A333341-070608, Chinese medicine Zhunzi J20030017, daily dosage, 20mg/day.
  • JZ type 300g tension transducer purchased from Gaobeidian Xinhang Accumulation Equipment Co., Ltd.
  • Medlab biological signal acquisition and processing system purchased from Nanjing Meiyi Technology Co., Ltd.
  • the orthogonal test method is used, and the dose and combination of the B drug and the G drug are optimized based on the time when the mouse is suspended.
  • the factor level table and the orthogonal test table are shown in Table 1 and Table 2.
  • mice 150 normal mice, randomly divided into 10 groups according to body weight, each group of 5 , that is, 1-9 groups, positive drug fluoxetine hydrochloride capsules (3.5 mg / kg / d), blank control group (administered 9 groups are equivalent to blank groups). Each group was administered at 0.2 ml/10 g body weight for 2 consecutive days.
  • Each of the above groups was administered continuously for 2 days, and the experiment was carried out 1 hour after the administration on the second day.
  • the tail end of the mouse (2 cm from the tip of the tail) was fixed on the line of the lOOg tension transducer with a tape to make it fall.
  • the head In the suspended state, the head is about 15 cm away from the test bench, and two animals are tested at the same time, separated from each other by cardboard.
  • the transducer is connected to the Medlab biosignal acquisition and processing system. After 2 min, the small suspension time within 4 min is recorded, and the immobile state is converted into time (s).
  • the best condition for the range analysis is B1G1, which is a combination of 80 mg of B medicine and 40 mg of G medicine.
  • the first group is the best condition, and in each administration group, the administration is the first.
  • the group had the shortest time of suspension and had a significant difference compared with the blank control group (PO.01).
  • B1G2 B medicine 80mg+G medicine 20mg
  • B2G1 B medicine 40mg+G medicine 40mg
  • B1G3 80 mg alone
  • B3G1 40 mg G alone
  • the combination of the pharmaceutical composition B1G1 (white peony extract 80 mg + licorice extract 40 mg), the pharmaceutical composition B1G2 (white peony extract 80 mg + licorice extract 20 mg)
  • the combination of the pharmaceutical composition B2G1 (white peony root extract 40mg + licorice extract 40m) can significantly shorten the time of mouse tail suspension (P ⁇ 0.01, compared with the blank group), and has significant antidepressant effect. .
  • ICR mice male, weighing 22.0 ⁇ 2g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Test drug The pharmaceutical composition of the present invention prepared in accordance with Example 1 is a capsule, and the positive drug: paroxetine (Selite), a product of Sino-US Tianjin Shike Pharmaceutical Co., Ltd.
  • thermometer GM222 type electronic thermometer, stopwatch.
  • the large dose of the test drug is 120mg kg/d
  • the medium dose is 60mg kg/d
  • the small dose is
  • mice were randomized into groups of 10: (1) High dose group of test drugs (UOmg*! ⁇ - 1 , Oral administration, administration 2d); (2) medium dose group (60mg *kg-l, intragastric administration, administration for 2d); (3) small dose group (SOmg *] ⁇ - 1 of the test drug Oral administration, administration 2d); (4) positive drug paroxetine group Gmg kg- 1 , gavage, administration 2d).
  • mice were placed in a glass jar with a water depth of 10 cm and a diameter of 14 cm, and the water temperature was 25 ° C. The cumulative immobility time of the mice in the water was recorded for 5 minutes.
  • the pharmaceutical composition of the present invention the ruthenium glutamate, the middle dose group and the paroxetine group can significantly shorten the cumulative time of forced swimming in mice, the middle dose group and the high dose group and the saline group ( There is a significant difference in the model group), so that it can be inferred that the pharmaceutical composition of the present invention, guanidine gum, has an anti-experimental depression function.
  • Experimental Example 6 Effect of Gadolin chinensis on Monoamine Neurotransmitter in Rats with Chronic Stress
  • Test drug The pharmaceutical composition of the present invention is guanidine gum; positive drug: fluoxetine hydrochloride (Prozac), provided by Lilly Suzhou Pharmaceutical Co., Ltd. (batch number: Chinese medicine standard J20030017).
  • Wistar male rats weighing 220g ⁇ 240g, were provided by Beijing Vital Lihua Company. All animals were purchased one week in advance and routinely reared.
  • sucrose water 72 normal rats, after 24 hours of water inadequacy, were given 1% sucrose water and measured the consumption within 1 hour. According to the consumption of sucrose water, it was randomly divided into 6 groups, 12 in each group, namely normal control group, model group, positive drug solution group (3.5mg kg/d), and glutinous gum high (100mg/kg/d). , medium (50mg kg/d), low (25mg/kg/d) dose group. Simultaneous administration of the model was performed once a day for 21 days. Each group was administered at a dose of 1.0 ml/100 g body weight, and the body weight was weighed once a week.
  • the animals were killed by decapitation, and the brain was quickly dissected on the ice.
  • the forehead cortex was taken.
  • the tissue was weighed and frozen in a frozen tube with liquid nitrogen, and then stored in a -70 °C refrigerator until the measurement.
  • the high performance liquid chromatography-electrochemical detector system (HPLC-ECD type, purchased from ESA Biosciences, Inc., USA) was used to determine the color: the color i column was 4 ⁇ 150 mm.
  • Blank group - 9 398.47 ⁇ 111.11* model group - 11 159.20 ⁇ 49.31 positive group 3.5mg/kg/d 8 440.88 ⁇ 152.58* ⁇ ⁇ ⁇ low dose group 25mg/kg/d 11 174.59 + 70.35 ⁇ capsule medium dose group 50mg/kg/d 11 345.19 ⁇ 133.43* ⁇ Gold ⁇ high dose group 100mg/kg/d 10 271.48 ⁇ 102.50 Compared with the model group, *P ⁇ 0.05, **P ⁇ 0.01
  • the results of the experimental study showed that the content of 5-HT and NE in the brain of rats with chronic stress was significantly decreased.
  • the medium and high dose group of the pharmaceutical composition of the present invention can significantly increase the content of 5-HT and NE in the brain, suggesting the drug of the present invention.
  • the composition may act as an antidepressant by elevating the expression of monoamine neurotransmitters in the brain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique préparée à partir de la racine de réglisse et de la racine de pivoine blanche ou des extraits de celles-ci destinée à traiter la dépression; ladite composition comprenant la glycyrrhizine ou l'énoxolone, la paeoniflorine et l'albiflorine etc. La présente invention concerne également un procédé de préparation de ladite composition et l'utilisation de ladite composition dans la fabrication de médicaments, d'aliments diététiques et/ou d'agents nutritionnels destinés à traiter la dépression et des complications, ou troubles liés à celle-ci.
PCT/CN2009/001409 2009-05-21 2009-12-09 Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci WO2010133015A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200980159383.4A CN102438630B (zh) 2009-05-21 2009-12-09 治疗抑郁症的药物组合物、制备方法及用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009101433362A CN101890082A (zh) 2009-05-21 2009-05-21 一组用于治疗抑郁症的药物组合物及制法
CN200910143336.2 2009-05-21

Publications (1)

Publication Number Publication Date
WO2010133015A1 true WO2010133015A1 (fr) 2010-11-25

Family

ID=43099540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/001409 WO2010133015A1 (fr) 2009-05-21 2009-12-09 Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci

Country Status (2)

Country Link
CN (2) CN101890082A (fr)
WO (1) WO2010133015A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068958A1 (fr) * 2010-11-25 2012-05-31 Zhang Zuoguang Utilisation de l'albiflorine ou d'un métabolite de celle-ci dans la lutte contre l'anxiété et pour l'amélioration de troubles du sommeil
CN103242393A (zh) * 2013-05-13 2013-08-14 兰州理工大学 大孔树脂分离甘草酸提取液分离纯化方法
FR3033699A1 (fr) * 2015-03-16 2016-09-23 Crodarom Extrait de pivoine de chine, composition comprenant ledit extrait et utilisation cosmetique
CN107412244A (zh) * 2016-10-11 2017-12-01 张作光 芍药内酯苷在制备改善褪黑素系统功能的产品中的用途
WO2018068566A1 (fr) * 2016-10-11 2018-04-19 张作光 Application de l'albiflorine dans la production de produits destinée à améliorer la fonction du système de la flore intestinale
US10363263B2 (en) * 2015-11-04 2019-07-30 Prescient Pharma, Llc Anti-aging compositions and methods for using same
CN110652004A (zh) * 2019-08-29 2020-01-07 北京康爱营养医学研究院 一种防治抑郁的营养组合物及其制备方法、应用
CN112438994A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种对双相情感障碍具有防治作用的小肠粘膜提取物
CN114272254A (zh) * 2020-09-28 2022-04-05 中国科学院上海药物研究所 甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105477126A (zh) * 2015-12-30 2016-04-13 广东药学院 一种用于治疗抑郁症的中药提取物组合物及其制备方法和应用
CN107184866A (zh) * 2017-06-01 2017-09-22 泉州医学高等专科学校 一种芍甘复方胶囊剂的制备工艺
CN112057526A (zh) * 2020-09-29 2020-12-11 浙江省中医药研究院 一种健脾解郁合剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413589A (zh) * 2002-10-29 2003-04-30 沈阳药科大学 芍药苷和芍药内酯苷的组合物及其制备方法
CN1579485A (zh) * 2004-03-16 2005-02-16 南京师范大学 治疗肠功能紊乱的中药组合物及其制备方法
CN101099770A (zh) * 2006-07-04 2008-01-09 北京中医药大学 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用
CN101332205A (zh) * 2007-06-25 2008-12-31 张作光 一种以芍药甙为原料的抗抑郁药物及其制法
CN101450063A (zh) * 2007-11-30 2009-06-10 戚郁芬 治疗忧郁症的口服药物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413589A (zh) * 2002-10-29 2003-04-30 沈阳药科大学 芍药苷和芍药内酯苷的组合物及其制备方法
CN1579485A (zh) * 2004-03-16 2005-02-16 南京师范大学 治疗肠功能紊乱的中药组合物及其制备方法
CN101099770A (zh) * 2006-07-04 2008-01-09 北京中医药大学 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用
CN101332205A (zh) * 2007-06-25 2008-12-31 张作光 一种以芍药甙为原料的抗抑郁药物及其制法
CN101450063A (zh) * 2007-11-30 2009-06-10 戚郁芬 治疗忧郁症的口服药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, DONG-FENG ET AL.: "Pharmacokinetics study on paeoniflorin in sini san.", CHINESE JOURNAL OF EXPERIMENTAL TRADITIONAL MEDICAL FORMULAE(CHINESE)., vol. 11, no. 2, April 2005 (2005-04-01), pages 36 - 38 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068958A1 (fr) * 2010-11-25 2012-05-31 Zhang Zuoguang Utilisation de l'albiflorine ou d'un métabolite de celle-ci dans la lutte contre l'anxiété et pour l'amélioration de troubles du sommeil
US9555055B2 (en) 2010-11-25 2017-01-31 Zuoguang Zhang Use of albiflorin and metabolites thereof
CN103242393A (zh) * 2013-05-13 2013-08-14 兰州理工大学 大孔树脂分离甘草酸提取液分离纯化方法
FR3033699A1 (fr) * 2015-03-16 2016-09-23 Crodarom Extrait de pivoine de chine, composition comprenant ledit extrait et utilisation cosmetique
US10363263B2 (en) * 2015-11-04 2019-07-30 Prescient Pharma, Llc Anti-aging compositions and methods for using same
WO2018068565A1 (fr) * 2016-10-11 2018-04-19 张作光 Application d'albiflorine dans la production de produits destinés à améliorer la fonction du système mélatonine
WO2018068566A1 (fr) * 2016-10-11 2018-04-19 张作光 Application de l'albiflorine dans la production de produits destinée à améliorer la fonction du système de la flore intestinale
CN107412244A (zh) * 2016-10-11 2017-12-01 张作光 芍药内酯苷在制备改善褪黑素系统功能的产品中的用途
US11020415B2 (en) 2016-10-11 2021-06-01 Zuoguang Zhang Use of albiflorin in preparation of products for improving function of intestinal flora system
CN110652004A (zh) * 2019-08-29 2020-01-07 北京康爱营养医学研究院 一种防治抑郁的营养组合物及其制备方法、应用
CN112438994A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种对双相情感障碍具有防治作用的小肠粘膜提取物
CN114272254A (zh) * 2020-09-28 2022-04-05 中国科学院上海药物研究所 甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用
CN114272254B (zh) * 2020-09-28 2024-01-26 中国科学院上海药物研究所 甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用

Also Published As

Publication number Publication date
CN102438630A (zh) 2012-05-02
CN101890082A (zh) 2010-11-24
CN102438630B (zh) 2015-03-18

Similar Documents

Publication Publication Date Title
WO2010133015A1 (fr) Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci
EP2450046B1 (fr) Composition à visée médicale pour le traitement de la bronchite et sa préparation
EP2491934B1 (fr) Utilisation d'albiflorine en tant qu'antidépresseur
TW200904461A (en) A pharmaceutical composition for treating depression and method for preparation thereof
US11504350B2 (en) Cannabinoid compositions and methods of use thereof
WO2014094632A1 (fr) Composition pharmaceutique pour le traitement de céphalées et procédé de préparation correspondant
KR101704918B1 (ko) 혼합 생약 추출물을 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 약학적 조성물
CN102014931B (zh) 芍药甙的抗抑郁症用途、制备方法及其药物组合物
WO2011003226A1 (fr) Composition pharmaceutique destinée au traitement de la dépression, sa méthode de préparation et son utilisation
He et al. Absorption properties of luteolin and apigenin in Genkwa Flos using in situ single-pass intestinal perfusion system in the rat
CN102526546A (zh) 一种中药组合物及其制剂和制备方法
WO2011088715A1 (fr) Utilisation d'albiflorine pour le traitement de la maladie de parkinson
WO2009070924A1 (fr) Compositions pharmaceutiques avec mécanisme à rétroaction par récepteur multi-cible pour le traitement de la dépression
CN101690755B (zh) 一种抗病毒提取物及其制备方法
CN102600312B (zh) 一种具有预防流行性感冒功效的药物组合物
CN102048967A (zh) 一种消炎解热的组合物及其制备方法
CN102188483B (zh) 一种治疗咽喉炎的提取物及其制备方法
CN107802678A (zh) 一种喉康散的制备方法
CN107582866B (zh) 铁皮石斛和氨氯地平在制备治疗高血压药物中的应用方法
CN109820883A (zh) 梁王茶属植物提取物及其药物组合物制备方法及其抗溃疡用途
KR101600745B1 (ko) 생약 추출물을 포함하는 신경안정용 약학적 조성물
US20050118287A1 (en) Use of a vanilloid as an anti-snoring element
CN108938785B (zh) 一种治疗咳嗽变异性哮喘的中药组合物及其制备方法
CN113995779A (zh) 一种柿叶提取物在治疗失眠中的应用
CN111759901B (zh) 一种治疗儿童功能性腹痛的中药组合物及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980159383.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09844768

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09844768

Country of ref document: EP

Kind code of ref document: A1